Evidence map›Paper›PMID 41669254›Full record

SynthesisFrontiers in oncology2025

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis.

Yuan Liu, Tongtong Ren, Xinchun Wang, Yuqi Wang, Lisha Tang, Wenjiang Cao

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuan Liu *The First Affiliated Hospital Shihezi University, Shihezi, Xinjiang, China.
Tongtong Ren *General Hospital of Xinjiang Military Region of the People's Liberation Army of China, Urumqi, Xinjiang, China.
Xinchun WangThe First Affiliated Hospital Shihezi University, Shihezi, Xinjiang, China.
Yuqi WangLianyungang Maternal and Child Health Hospital Affiliated to Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, China.
Lisha TangLianyungang Maternal and Child Health Hospital Affiliated to Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, China.
Wenjiang CaoThe First Affiliated Hospital Shihezi University, Shihezi, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The incidence of ovarian cancer ranks second only to cervical cancer and uterine cancer, but its mortality rate is the highest. Searching for effective and safe PARP inhibitors - antiangiogenic drugs combined treatment for ovarian cancer is a new approach. Method: Conducted a comprehensive search in the authoritative databases, with the search period ranging from the establishment of these databases until December 2024. And conducted a Bayesian network meta-analysis using R 4.3.1 and Stata 16.0.The primary endpoint was progression-free survival (PFS), and the secondary endpoint was adverse events (AEs) (≥grade 3). Results: The analysis ultimately incorporated 15 RCTs from 18 publications, involving 6,416 patients and evaluating nine distinct treatment regimens. All PARPi monotherapies and combination therapies demonstrated significant PFS improvement versus placebo (P ≤ 0.05). Compared with niraparib alone(HR = 2.85; 95%CI:1.2-6.79), niraparib+bevacizumab showed significant difference in improving PFS in ovarian cancer patients (P ≤ 0.05). olaparib+cediranib had significant difference in improving PFS compared with olaparib(HR = 1.36; 95%CI:1.06-2.26) (P ≤ 0.05). Besides, niraparib+bevacizumab ranked first in improving PFS, followed by olaparib+ cediranib. In terms of safety, there was no statistically significant difference in AEs (grade≥3) between different PARP inhibitors or in combination with antiangiogenic agents for ovarian cancer. Conclusion: Current evidence indicates that the combination of PARPi and anti-angiogenic drugs in the treatment of ovarian cancer is superior to PARPi monotherapy. Niraparib combined with bevacizumab may show the most optimal effect in improving PFS, and it might be a better combined treatment option. In monotherapy, senaparib has shown good efficacy. The incidence of AEs of various PARPi is similar, but the incidence of adverse reactions is relatively high when used in combination mode. A reasonable treatment plan should be selected based on the individual conditions of patients. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD 420251003413.

Indexed as

antiangiogenic agentsefficacyovarian cancerPARP inhibitorssafety

Identifiers

PMID41669254
PMCPMC12883406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.